NNMT Biology and Metabolic Role
What NNMT Does
NNMT catalyzes the transfer of a methyl group from SAM to nicotinamide, consuming both the methyl group and the nicotinamide simultaneously:SAM + Nicotinamide → SAH + 1-Methylnicotinamide
This reaction has two metabolically significant consequences: 1. Nicotinamide depletion: Nicotinamide is a NAD+ precursor. NNMT activity removes nicotinamide from the NAD+ synthesis pathway, reducing NAD+ availability. 2. SAM consumption: SAM is the universal methyl donor for >200 methylation reactions including DNA methylation, histone methylation, and neurotransmitter synthesis. NNMT acts as a metabolic "methyl sink," draining SAM without productive purpose.
NNMT in Adipose Tissue
NNMT is highly expressed in white adipose tissue (WAT). In obesity, adipose NNMT is significantly upregulated, creating a vicious cycle: high NNMT activity depletes NAD+ and SAM, impairing mitochondrial function, reducing fatty acid oxidation, and reducing the methylation capacity needed for proper gene expression. Preclinical models of NNMT knockdown show protection against diet-induced obesity and insulin resistance.5-Amino-1MQ as an NNMT Inhibitor
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule that competitively inhibits NNMT by occupying its nicotinamide binding site. It is not a peptide but is often grouped with metabolic research compounds in the peptide community.
Mechanism
By blocking NNMT, 5-Amino-1MQ: - Preserves nicotinamide → increases NAD+ synthesis flux - Preserves SAM → restores cellular methylation capacity - Reduces 1-MNA production, which itself has complex biological effectsPreclinical Evidence
Mouse models have shown that 5-Amino-1MQ treatment leads to: - Reduced adipose mass without caloric restriction - Improved insulin sensitivity - Increased energy expenditure - Upregulation of genes involved in mitochondrial biogenesisNo human clinical trials on 5-Amino-1MQ have been completed as of 2025. All effects are from rodent preclinical data.
Stacking with Metabolic Peptides
NNMT inhibition has logical complementarity with several metabolic peptides:
MOTS-c
MOTS-c activates AMPK and drives flux through one-carbon metabolism. Since NNMT inhibition preserves both SAM (used in methylation) and nicotinamide (used in NAD+ synthesis), combining 5-Amino-1MQ with MOTS-c theoretically removes two metabolic constraints that might otherwise limit MOTS-c's downstream effects. This is the most discussed stack in the community.GLP-1 Analogs (Semaglutide, Tirzepatide)
GLP-1 receptor agonists work via incretin-mediated insulin secretion and satiety signaling. NNMT inhibition addresses a different axis, adipose metabolic dysfunction. The combination targets both appetite regulation (GLP-1) and adipose remodeling (NNMT inhibition). Some researchers hypothesize NNMT inhibition may address fat loss that plateaus on GLP-1 therapy.NAD+ Precursors (NR, NMN)
NR and NMN raise NAD+ by providing substrate. NNMT inhibition conserves nicotinamide, complementing precursor supplementation. In theory: precursors increase the NAD+ input and NNMT inhibition reduces the drain. In practice, this combination has not been studied.Safety and Research Status
5-Amino-1MQ has no published human safety data as of 2025. All dosing used in the research community is extrapolated from rodent studies with dose conversion adjustments.
Theoretical concerns: - 1-MNA (the product NNMT makes) has protective cardiovascular and neurological roles in some contexts, systemic NNMT inhibition may reduce 1-MNA in tissues where it is beneficial - SAM excess from reduced NNMT activity could theoretically affect methylation balance, particularly in high-dose or prolonged use
Research use only. Not approved for human use. Consult a physician before use.
References
- [1]Ryu D, et al. "A SIRT7-Dependent Acetylation Switch of GABPbeta1 Controls Mitochondrial Function." Cell Metabolism. 2014.
- [2]Kannt A, et al. "Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with characteristics of the metabolic syndrome." Diabetologia. 2015.
- [3]Hong S, et al. "Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization." Nature Medicine. 2015.
- [4]Neelakantan H, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochemical Pharmacology. 2018.